Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.

Smith VM, Lomas O, Constantine D, Palmer L, Schuh AH, Bruce D, Gonchar O, Macip S, Jayne S, Dyer MJS, Eyre TA.

Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917. No abstract available.

PMID:
32040552
2.

Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.

McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J, Crosbie N, Rule S.

Br J Haematol. 2020 Feb 3. doi: 10.1111/bjh.16416. [Epub ahead of print]

PMID:
32011729
3.

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.

Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM.

Br J Haematol. 2020 Jan 29. doi: 10.1111/bjh.16451. [Epub ahead of print]

PMID:
31997308
4.

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.

Djebbari F, Panitsas F, Eyre TA, Prodger C, Davies F, Burton K, Khera A, Vallance G, Moore S, Kothari J, Peniket A, Ramasamy K.

Haematologica. 2020 Jan 9. pii: haematol.2019.240762. doi: 10.3324/haematol.2019.240762. [Epub ahead of print] No abstract available.

5.

Correction: Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era.

Sharpley FA, Neffa P, Panitsas F, Eyre TA, Kothari J, Subesinghe M, Cutter D, Szor RS, Martinez GA, Rocha V, Ramasamy K.

PLoS One. 2019 Nov 7;14(11):e0225184. doi: 10.1371/journal.pone.0225184. eCollection 2019.

6.

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16271. [Epub ahead of print]

PMID:
31682002
7.

Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas.

Eyre TA.

Br J Haematol. 2020 Jan;188(2):202-204. doi: 10.1111/bjh.16259. Epub 2019 Nov 4. No abstract available.

PMID:
31680237
8.

A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.

Eyre TA, Djebbari F, Kirkwood AA, Collins GP.

Haematologica. 2019 Sep 5. pii: haematol.2019.229948. doi: 10.3324/haematol.2019.229948. [Epub ahead of print]

9.

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.

Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP.

Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9.

PMID:
31385336
10.

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.

Kesavan M, Eyre TA, Collins GP.

Curr Hematol Malig Rep. 2019 Aug;14(4):207-218. doi: 10.1007/s11899-019-00518-8. Review.

11.

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.

Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR.

Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20.

PMID:
31222719
12.

Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.

Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora SM, Hatton CSR, Collins GP, Eyre TA.

Br J Haematol. 2019 Sep;186(6):e191-e195. doi: 10.1111/bjh.16071. Epub 2019 Jun 20. No abstract available.

PMID:
31222716
14.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

15.

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR.

Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. No abstract available.

PMID:
31020646
16.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
17.

Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?

Eyre TA.

Oncotarget. 2019 Feb 26;10(17):1661. doi: 10.18632/oncotarget.26767. eCollection 2019 Feb 26.

18.

Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR.

J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11.

PMID:
30811713
19.

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, Cross M, Forconi F, Shah N, Chasty R, Hart A, Broom A, Marr H, Patten PEM, Dann A, Arumainathan A, Munir T, Shankara P, Bloor A, Johnston R, Orchard K, Schuh AH, Fox CP; the UK CLL Forum.

Br J Haematol. 2019 May;185(4):656-669. doi: 10.1111/bjh.15802. Epub 2019 Feb 15.

PMID:
30768675
20.

Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?

Eyre TA.

Oncotarget. 2018 Dec 18;9(99):37280-37281. doi: 10.18632/oncotarget.26460. eCollection 2018 Dec 18. No abstract available. Erratum in: Oncotarget. 2019 Feb 26;10(17):1661.

21.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
22.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

23.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

24.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

25.

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Eyre TA, Fox CP, Boden A, Bloor A, Dungawalla M, Shankara P, Went R, Schuh AH.

Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22. No abstract available.

PMID:
29468637
26.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.

Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP.

Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Erratum in: Br J Haematol. 2018 Jan;180(2):309.

PMID:
28857136
27.

Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.

Brierley CK, Eyre TA.

Blood. 2017 Jun 22;129(25):3396. doi: 10.1182/blood-2017-03-765776. No abstract available.

PMID:
28642361
28.

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.

Kassam S, Chernucha E, O'Neill A, Hemmaway C, Cummins T, Montoto S, Lennard A, Adams G, Linton K, McKay P, Davies D, Rowntree C, Easdale S, Eyre TA, Marcus R, Cwynarski K, Fox CP.

Bone Marrow Transplant. 2017 Sep;52(9):1268-1272. doi: 10.1038/bmt.2017.101. Epub 2017 Jun 5.

PMID:
28581466
29.

An update for Richter syndrome - new directions and developments.

Eyre TA, Schuh A.

Br J Haematol. 2017 Aug;178(4):508-520. doi: 10.1111/bjh.14700. Epub 2017 Apr 25. Review.

PMID:
28439883
30.

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.

PMID:
28342183
31.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
32.

Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review.

Soilleux EJ, Wotherspoon A, Eyre TA, Clifford R, Cabes M, Schuh AH.

Histopathology. 2016 Dec;69(6):1066-1076. doi: 10.1111/his.13024. Epub 2016 Sep 9.

PMID:
27345622
33.

Multiple myeloma in the very elderly patient: challenges and solutions.

Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K.

Clin Interv Aging. 2016 Apr 15;11:423-35. doi: 10.2147/CIA.S89465. eCollection 2016. Review.

34.

Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.

Eyre TA, Fox CP, Shankara P, Went R, Schuh AH.

Br J Haematol. 2017 May;177(3):486-491. doi: 10.1111/bjh.14066. Epub 2016 Apr 7. No abstract available.

PMID:
27061924
35.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.

Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS.

Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9.

PMID:
26956150
36.

Acute EBV masquerading as peripheral T-cell lymphoma.

Zhang XY, Collins GP, Soilleux E, Eyre TA.

BMJ Case Rep. 2016 Feb 2;2016. pii: bcr2015213573. doi: 10.1136/bcr-2015-213573.

37.

Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.

Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS.

Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29. No abstract available.

PMID:
26223361
38.

Immune checkpoint inhibition in lymphoid disease.

Eyre TA, Collins GP.

Br J Haematol. 2015 Aug;170(3):291-304. doi: 10.1111/bjh.13397. Epub 2015 Mar 30. Review.

PMID:
25824455
39.

Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2.

Eyre TA, Bignell P, Keeling D.

Blood Coagul Fibrinolysis. 2015 Apr;26(3):352-3. doi: 10.1097/MBC.0000000000000265. No abstract available.

PMID:
25803519
40.

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.

Eyre TA, Clifford R, Roberts C, Boyle L, Francis A, Schuh A, Dutton SJ.

BMC Cancer. 2015 Feb 13;15:52. doi: 10.1186/s12885-015-1048-9.

41.

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.

Collins GP, Eyre TA, Linton KM, Radford J, Vallance GD, Soilleux E, Hatton C.

Br J Haematol. 2015 Sep;170(6):886-90. doi: 10.1111/bjh.13333. Epub 2015 Feb 26. No abstract available.

PMID:
25721307
42.

Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.

Eyre TA, Gatter K, Collins GP, Hall GW, Watson C, Hatton CS.

Am J Hematol. 2015 Jun;90(6):E103-10. doi: 10.1002/ajh.23989. Epub 2015 May 4.

43.

Management and controversies of classical Hodgkin lymphoma in pregnancy.

Eyre TA, Lau IJ, Mackillop L, Collins GP.

Br J Haematol. 2015 Jun;169(5):613-30. doi: 10.1111/bjh.13327. Epub 2015 Feb 13. Review.

PMID:
25684034
44.

Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).

Sims MC, Newell K, Eyre TA, Hatton C, Collins GP.

Br J Haematol. 2015 May;169(3):452-5. doi: 10.1111/bjh.13226. Epub 2014 Nov 16. No abstract available.

PMID:
25399667
45.

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.

Eyre TA, Collins GP, Goldstone AH, Cwynarski K.

Br J Haematol. 2014 Aug;166(3):336-51. doi: 10.1111/bjh.12945. Epub 2014 May 19. Review.

PMID:
24842496
46.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.

Eyre TA, Khan D, Hall GW, Collins GP.

Eur J Haematol. 2014 Dec;93(6):455-68. doi: 10.1111/ejh.12360. Epub 2014 May 21. Review.

PMID:
24766435
47.

Dutcher bodies: cytoplasmic inclusions within the nucleus.

Eyre TA, Littlewood TJ, Bain BJ.

Br J Haematol. 2014 Sep;166(6):946-7. doi: 10.1111/bjh.12911. Epub 2014 Apr 18. No abstract available.

PMID:
24749887
48.

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Eyre TA, Gooding S, Patel I, Moore N, Hatton C, Collins GP.

Int J Hematol. 2014 Jun;99(6):798-800. doi: 10.1007/s12185-014-1555-5. Epub 2014 Mar 2.

PMID:
24584910
49.

T-cell/histiocyte-rich large B-cell lymphoma--transformation of nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow.

Eyre TA, King AJ, Hatton C, Collins GP.

Eur J Haematol. 2014 Jun;92(6):550-1. doi: 10.1111/ejh.12278. Epub 2014 Feb 21. No abstract available.

PMID:
24483596
50.

Classical Hodgkin's lymphoma: past, present and future perspectives.

Eyre TA, King AJ, Collins GP.

Br J Hosp Med (Lond). 2013 Nov;74(11):612-8. Review. No abstract available.

PMID:
24220522

Supplemental Content

Support Center